EFFECT OF TOBRAMYCIN INHALATION SOLUTION ON MORTALITY IN SUBGROUPS OF PATIENTS WITH CYSTIC FIBROSIS

被引：0
|
作者：
Latremouille-Viau, D. [1 ]
Sawicki, G. S. [2 ]
Zhang, J. [3 ]
von Wartburg, M. [1 ]
Signorovitch, J. [1 ]
Wu, E. Q. [1 ]
Shi, L. [4 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Childrens Hosp, Div Resp Dis, Boston, MA 02115 USA
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Tulane Univ, New Orleans, LA 70118 USA
来源：
PEDIATRIC PULMONOLOGY | 2011年
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：346 / 346
页数：1
相关论文
共 50 条
  • [21] Tobramycin Inhalation Powder (Tobi Podhaler) for Cystic Fibrosis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2013, 55 (1419): : 51 - 52
  • [22] Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements
    Chuchalin, Alexander
    Amelina, Elena
    Bianco, Federico
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2009, 22 (06) : 526 - 532
  • [23] ANTIPSEUDOMONAL ANTIBIOTICS USE AND HOSPITALIZATIONS FOR PULMONARY EXACERBATIONS IN CYSTIC FIBROSIS PATIENTS TREATED WITH TOBRAMYCIN INHALATION POWDER, TOBRAMYCIN INHALATION SOLUTION OR AZTREONAM FOR INHALATION SOLUTION: A RETROSPECTIVE STUDY OF US HEALTH CLAIMS DATABASES
    Osman, K.
    Dhariwal, M.
    Conti, V
    McSharry, M.
    Zhou, W.
    Chandra, R.
    PEDIATRIC PULMONOLOGY, 2018, 53 : 452 - 452
  • [24] Budget Impact Model of Adding Tobramycin Inhalation Solution for Treatment of Pseudomonas aeruginosa in Cystic Fibrosis Patients.
    Woodward, T. C.
    Sacco, P.
    Brown, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [25] COST IMPACT OF INITIATION OF TOBRAMYCIN SOLUTION FOR INHALATION (TSI) IN PATIENTS WITH CYSTIC FIBROSIS (CF) IN A MANAGED CARE POPULATION
    Kuhn, R. J.
    Wertz, D. A.
    Zhang, J.
    Chang, C.
    Stephenson, J. J.
    PEDIATRIC PULMONOLOGY, 2010, : 367 - 368
  • [26] Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection
    Quittner, AL
    Buu, A
    PEDIATRIC PULMONOLOGY, 2002, 33 (04) : 269 - 276
  • [27] Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
    Akkerman-Nijland, Anne M.
    Yousofi, Mina
    Rottier, Bart L.
    Van der Vaart, Hester
    Burgerhof, Johannes G. M.
    Frijlink, Henderik W.
    Touw, Daan J.
    Koppelman, Gerard H.
    Akkerman, Onno W.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2020, 14
  • [28] USE OF INHALED TOBRAMYCIN IS ASSOCIATED WITH REDUCED MORTALITY IN PATIENTS WITH CYSTIC FIBROSIS
    Signorovitch, J.
    Sawicki, G. S.
    Zhang, J.
    Latremouille-Viau, D.
    Wu, E. Q.
    von Wartburg, M.
    Lizheng, S.
    VALUE IN HEALTH, 2011, 14 (03) : A138 - A138
  • [29] USE OF INHALED TOBRAMYCIN IS ASSOCIATED WITH REDUCED MORTALITY IN PATIENTS WITH CYSTIC FIBROSIS
    Sawicki, G. S.
    Signorovitch, J.
    Latremouille-Viau, D.
    von Wartburg, M.
    Wu, E.
    Zhang, J.
    Shi, L.
    PEDIATRIC PULMONOLOGY, 2010, : 363 - 364
  • [30] Tobramycin inhalation product approved for use in cystic fibrosis therapy
    Nightingale, SL
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (09): : 645 - 645
12345